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Introduction
Intravesical BCG is an example of the importance of
immunotherapy in cancer treatment. It has been used
since the 1970s as it has a major impact in preventing or
delaying bladder cancer recurrence and possibly progres-
sion. Unfortunately 20-30% of patients who receive this
treatment do not respond and they are at high risk of
dying from their disease. Being able to predict response to
treatment would be an invaluable tool in those patients
and would help in directing them to the appropriate treat-
ment modalities. We investigated whether immunological
markers in blood can predict outcome.
Methods
Patients with high risk non-invasive bladder cancer and
due to have BCG immunotherapy were included. Blood
samples were obtained before and after BCG-induction
treatment. In vitro stimulation of peripheral-blood
mononuclear cells with PPD which were then labelled
with extra and intracellular markers in order to assess
the differentiation and activation status of T-cells.
Results
13 patients had no recurrence on follow-up cystoscopy
while 6 had persistent disease. Differences were seen
between the two groups in mean percentage of Interferon
gamma positive (INFg+) CD4 in response to PPD stimula-
tion; 1.84% (±1.58) in the recurrence-free group versus
0.54% (±0.72) in the recurrence group [P value 0.0252].
This was more clear in the specialised subset [CCR7-
CD27-CD28+]; 2.46% (±1.96) and 0.77% (±0.80) respec-
tively [P value 0.0168]. And in the [CCR7-CD27-CD28+]
subset; 5.07% (±4.19) and 1.12% (±1.25) respectively
[P Value 0.0067]. The mean percentages of pre-treatment
tumour necrosis factor positive (TNF+) cells were also sig-
nificantly different in the [CCR7-CD27-CD28+] subset;
8.82% (±6.06) and 3.10% (±3.81) respectively [P value
0.0246].
Conclusion
In bladder cancer immunotherapy, the percentage of PPD
inducible INFg+ and TNF+ CD4 cells can potentially pre-
dict outcome to treatment.
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